Surrozen’s (SRZN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Surrozen (NASDAQ:SRZN) in a research report report published on Tuesday,Benzinga reports. HC Wainwright currently has a $36.00 target price on the stock, up from their previous target price of $32.00. HC Wainwright also issued estimates for Surrozen’s Q1 2026 earnings at ($0.72) EPS, Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($0.98) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.70) EPS, FY2027 earnings at ($3.70) EPS, FY2028 earnings at ($3.89) EPS, FY2029 earnings at ($3.97) EPS and FY2030 earnings at ($3.54) EPS.

SRZN has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Surrozen to a “sell” rating in a report on Friday, November 28th. Finally, Cantor Fitzgerald initiated coverage on shares of Surrozen in a research report on Thursday, February 19th. They set an “overweight” rating and a $40.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Surrozen has an average rating of “Moderate Buy” and an average price target of $38.00.

Surrozen Stock Up 7.1%

Shares of SRZN stock opened at $28.00 on Tuesday. The company has a market cap of $239.96 million, a P/E ratio of -0.84 and a beta of 0.53. The business has a 50 day moving average of $24.50 and a two-hundred day moving average of $18.87. Surrozen has a 52 week low of $5.90 and a 52 week high of $29.59.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.29) by ($6.30). The company had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.66 million. Surrozen had a negative return on equity of 1,240.42% and a negative net margin of 7,476.67%. Analysts expect that Surrozen will post -8.49 EPS for the current fiscal year.

Insider Buying and Selling

In other Surrozen news, Director Tim Kutzkey purchased 18,052 shares of Surrozen stock in a transaction on Tuesday, January 20th. The stock was bought at an average price of $19.60 per share, for a total transaction of $353,819.20. Following the transaction, the director owned 1,016,658 shares of the company’s stock, valued at $19,926,496.80. The trade was a 1.81% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Tcg Crossover Gp Ii, Llc purchased 106,658 shares of the firm’s stock in a transaction dated Tuesday, March 24th. The stock was acquired at an average cost of $24.69 per share, with a total value of $2,633,386.02. Following the purchase, the insider owned 736,554 shares of the company’s stock, valued at approximately $18,185,518.26. This represents a 16.93% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 330,291 shares of company stock valued at $7,478,785 in the last three months. 45.18% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Surrozen

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its holdings in Surrozen by 50.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares during the period. Persistent Asset Partners Ltd acquired a new position in Surrozen during the 4th quarter valued at about $99,000. Citadel Advisors LLC increased its stake in Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after buying an additional 3,424 shares during the period. Marshall Wace LLP bought a new stake in shares of Surrozen during the 4th quarter worth about $247,000. Finally, Geode Capital Management LLC raised its position in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after buying an additional 5,702 shares in the last quarter. 66.57% of the stock is currently owned by institutional investors.

Trending Headlines about Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Large insider buys by major shareholder TCG Crossover GP II — the fund bought 106,658 shares on March 24 (~$24.69 avg) and has repeatedly purchased stock in March, signaling strong insider conviction that can support the share price. SEC Filing
• Positive Sentiment: Additional TCG purchase: 15,223 shares on March 23 (~$24.90 avg), a follow-on buy that reinforces the insider buying narrative. InsiderTrades article
• Positive Sentiment: HC Wainwright reiterated a “Buy”, raised multi-quarter and multi-year EPS projections (less negative) and set a $36 price target — a constructive analyst view that can attract demand. Article
• Positive Sentiment: Cantor Fitzgerald assigned an “Overweight” rating with a higher price target (reported this week), providing another institutional buy-side signal. Article
• Neutral Sentiment: Institutional ownership is high (many hedge funds hold SRZN) and several institutions increased positions in recent quarters — supportive for liquidity but not an immediate catalyst.
• Negative Sentiment: Lifesci Capital cut multiple near-term EPS estimates (Q1–Q4 2026 and FY2026), making its outlook more pessimistic and creating downside pressure for sentiment. MarketBeat coverage
• Negative Sentiment: Recent quarterly results (reported March 23) were a significant miss (EPS deeply negative vs. expectations) and the company remains loss-making with volatile margins — a fundamental risk that keeps shares speculative despite positive headlines. Earnings detail

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.